Marc Essodaigui
Directeur Général chez Active Biomarkers SASU
Profil
Marc Essodaigui is currently the General Manager at Active Biomarkers SASU since 2016.
Prior to this, he held positions as Director of Business Development at RELX Plc, Director of Sales & Marketing at QIAGEN Marseille SA, and General Manager at ABL Lyon SAS.
Dr. Essodaigui received a doctorate degree from Université Pierre et Marie Curie in 1998.
Postes actifs de Marc Essodaigui
| Sociétés | Poste | Début |
|---|---|---|
Active Biomarkers SASU
 Active Biomarkers SASU Medical/Nursing ServicesHealth Services Part of KCAS LLC, Active Biomarkers SASU is a French company that specializes in immuno-monitoring services. The company is based in Lyon, France. The company has a decade of experience in developing and performing assays for immuno-monitoring. Active Biomarkers provides services to support preclinical studies and human clinical trials in immune-related pathologies and neurological disorders. The company is an expert in the development, validation, and testing of assays for soluble or cellular biomarkers. The company's functional assays are designed to help understand the mechanism of action of the drug/therapy, while their pharmacodynamic/pharmacokinetic (pk/pd) assays help to understand the relationship between therapy and the patient biological system. The company was founded in 2011. Marc Essodaigui has been the CEO of the company since 2016. Active Biomarkers was acquired by KCAS LLC on September 12, 2022. | Directeur Général | 01/07/2016 |
Anciens postes connus de Marc Essodaigui
| Sociétés | Poste | Fin |
|---|---|---|
| RELX PLC | Corporate Officer/Principal | - |
ABL Lyon SAS
 ABL Lyon SAS BiotechnologyHealth Technology ABL Lyon SAS provides biomarker testing services to advance therapies from discovery to clinical stages. Its services and solutions include immunophenotyping, functional assays, drug-target interactions, study design, sampling plans, and logistics. The company was founded in 2011 and is headquartered in Lyon, France. | Directeur Général | - |
| QIAGEN MARSEILLE | Sales & Marketing | - |
Formation de Marc Essodaigui
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| RELX PLC | Commercial Services |
| Entreprise privées | 4 |
|---|---|
QIAGEN Marseille SA
 QIAGEN Marseille SA Miscellaneous Commercial ServicesCommercial Services QIAGEN Marseille SA is a molecular diagnosis company, which focuses on the development and marketing of diagnostic tests in the field of oncology. Its products are used for diagnosis, prognosis and monitoring of patients with leukemia. The company was founded by Vincent Fert, Stéphane Debono, and Fabienne Hermitte on September 23, 1999 and is headquartered in Marseille, France. | Commercial Services |
| Université Pierre et Marie Curie | Consumer Services |
ABL Lyon SAS
ABL Lyon SAS BiotechnologyHealth Technology ABL Lyon SAS provides biomarker testing services to advance therapies from discovery to clinical stages. Its services and solutions include immunophenotyping, functional assays, drug-target interactions, study design, sampling plans, and logistics. The company was founded in 2011 and is headquartered in Lyon, France. | Health Technology |
Active Biomarkers SASU
Active Biomarkers SASU Medical/Nursing ServicesHealth Services Part of KCAS LLC, Active Biomarkers SASU is a French company that specializes in immuno-monitoring services. The company is based in Lyon, France. The company has a decade of experience in developing and performing assays for immuno-monitoring. Active Biomarkers provides services to support preclinical studies and human clinical trials in immune-related pathologies and neurological disorders. The company is an expert in the development, validation, and testing of assays for soluble or cellular biomarkers. The company's functional assays are designed to help understand the mechanism of action of the drug/therapy, while their pharmacodynamic/pharmacokinetic (pk/pd) assays help to understand the relationship between therapy and the patient biological system. The company was founded in 2011. Marc Essodaigui has been the CEO of the company since 2016. Active Biomarkers was acquired by KCAS LLC on September 12, 2022. | Health Services |
